<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
                    <title>Urology</title>
            <link>https://medicalxpress.com/urology-news/</link>
            <language>en-us</language> 
            <description>Latest medical news and research in Urology</description>

                            <item>
                    <title>Severe male infertility tied to higher colorectal and thyroid cancer risk</title>
                    <description>Men with severely reduced fertility are at greater risk of developing other health conditions later in life. A research team from Lund University in Sweden has now shown that these men are also more likely to develop colorectal cancer and thyroid cancer.</description>
                    <link>https://medicalxpress.com/news/2026-04-severe-male-infertility-higher-colorectal.html</link>
                    <category></category>
                    <pubDate>Thu, 16 Apr 2026 14:20:06 EDT</pubDate>
                    <guid isPermaLink="false">news695561041</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/link-between-male-infe.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>A major cancer protein hijacks RNA editing, exposing a new weakness in prostate tumors</title>
                    <description>Northwestern Medicine scientists have uncovered an unexpected role for a well-known cancer-related protein, revealing a new layer of genetic regulation that could reshape how certain cancers are treated. In a new study published in Nature Communications, investigators found that EZH2—a protein long recognized for its role in modifying DNA-packaging histones—also plays a direct and previously unknown role in RNA editing in prostate cancer.</description>
                    <link>https://medicalxpress.com/news/2026-04-major-cancer-protein-hijacks-rna.html</link>
                    <category></category>
                    <pubDate>Wed, 15 Apr 2026 17:20:05 EDT</pubDate>
                    <guid isPermaLink="false">news695487721</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/cancer-4.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Researchers map prostate immune niches, showing T cells persist months in mice</title>
                    <description>More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell weaponry we might use to save lives.</description>
                    <link>https://medicalxpress.com/news/2026-04-prostate-immune-niches-cells-persist.html</link>
                    <category></category>
                    <pubDate>Sat, 11 Apr 2026 10:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news694774170</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/scientists-discover-ho-4.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Long non-coding RNA may be a promising therapeutic target for cancer</title>
                    <description>Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways in prostate cancer cells and drives tumor progression, underscoring its potential as a therapeutic target, according to a recent study published in Nature Communications. Rendong Yang, Ph.D., associate professor of Urology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was co-corresponding author of the study.</description>
                    <link>https://medicalxpress.com/news/2026-04-coding-rna-therapeutic-cancer.html</link>
                    <category></category>
                    <pubDate>Thu, 09 Apr 2026 16:00:04 EDT</pubDate>
                    <guid isPermaLink="false">news694965789</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2021/prostate-cancer-2.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>A urine test that could change the course of bladder cancer care</title>
                    <description>Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called non-muscle invasive bladder cancer (NMIBC), in which the tumors are confined to the inner layers of the bladder. Despite early detection, the disease frequently returns.</description>
                    <link>https://medicalxpress.com/news/2026-04-urine-bladder-cancer.html</link>
                    <category></category>
                    <pubDate>Wed, 08 Apr 2026 12:20:06 EDT</pubDate>
                    <guid isPermaLink="false">news694867082</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/a-urine-test-that-coul.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>A big step toward safe, reversible male contraception</title>
                    <description>Cornell scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive, considered the holy grail of male contraception. A proof-of-principle study in mice, six years in the making, shows how targeting a natural checkpoint in meiosis, the process by which sex cells reproduce, safely stopped sperm production. The study is published in the journal Proceedings of the National Academy of Sciences.</description>
                    <link>https://medicalxpress.com/news/2026-04-big-safe-reversible-male-contraception.html</link>
                    <category></category>
                    <pubDate>Tue, 07 Apr 2026 16:20:03 EDT</pubDate>
                    <guid isPermaLink="false">news694791661</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/breakthrough-takes-big.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Innovative targeted therapy halts prostate cancer spread to the bone</title>
                    <description>New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in Pharmacological Research, show that an innovative drug effectively prevents prostate tumors from spreading to an advanced and incurable stage in the bones. The targeted small molecule inhibitor, IVMT-Rx-4, also enhances standard-of-care chemotherapy treatment for the disease, offering significant potential for a paradigm shift in the treatment of metastatic tumors.</description>
                    <link>https://medicalxpress.com/news/2026-04-therapy-halts-prostate-cancer-bone.html</link>
                    <category></category>
                    <pubDate>Thu, 02 Apr 2026 19:00:02 EDT</pubDate>
                    <guid isPermaLink="false">news694365242</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/innovative-targeted-th.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>PSMA therapy delays hormone therapy in prostate cancer, clinical trial finds</title>
                    <description>Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is also effective in an earlier stage of the disease. As a result, more burdensome hormone therapy can be postponed by twenty additional months, shows research led by Radboudumc.</description>
                    <link>https://medicalxpress.com/news/2026-03-psma-therapy-delays-hormone-prostate.html</link>
                    <category></category>
                    <pubDate>Tue, 31 Mar 2026 12:20:05 EDT</pubDate>
                    <guid isPermaLink="false">news694174321</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/psma-therapy-delays-ho.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Clinical trial finds hormone patches to be effective for locally advanced prostate cancer</title>
                    <description>Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL (University College London) researchers. Men with cancer that has spread just outside the prostate are given hormone therapy to suppress levels of testosterone which the cancer needs to grow. Most commonly, this is done by injections of drugs that block testosterone production.</description>
                    <link>https://medicalxpress.com/news/2026-03-clinical-trial-hormone-patches-effective.html</link>
                    <category></category>
                    <pubDate>Wed, 25 Mar 2026 17:00:03 EDT</pubDate>
                    <guid isPermaLink="false">news693656101</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2024/man-at-home.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Cellular &#039;atlas&#039; of prostate cancer opens new avenues for earlier detection</title>
                    <description>Prostate cancer affects one in five Australian men, making it the most common cancer in the country. Now, researchers at the Garvan Institute of Medical Research have produced the world&#039;s most detailed cellular &quot;atlas&quot; of early-stage prostate cancer, revealing the earliest changes that lead to the disease.</description>
                    <link>https://medicalxpress.com/news/2026-03-cellular-atlas-prostate-cancer-avenues.html</link>
                    <category></category>
                    <pubDate>Wed, 25 Mar 2026 10:00:12 EDT</pubDate>
                    <guid isPermaLink="false">news693651361</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/cellular-atlas-of-pros.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Largest study of its kind tests hydration strategy for kidney stones</title>
                    <description>Kidney stones can cause some of the most intense pain people ever experience, affecting daily life and leading many to hospital emergency visits. It affects one in 11 people in the U.S., and almost half will experience a recurrence. A major new study from the Urinary Stone Disease Research Network, coordinated by the Duke Clinical Research Institute, tested whether a behavioral program could help people drink enough fluids to prevent stones from coming back.</description>
                    <link>https://medicalxpress.com/news/2026-03-largest-kind-hydration-strategy-kidney.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Mar 2026 19:30:01 EDT</pubDate>
                    <guid isPermaLink="false">news693131101</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/drinking-water.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Early intervention in severe fetal megacystis can increase survival rate and kidney function</title>
                    <description>An interdisciplinary team from the University Hospitals Cologne and Bonn have conducted the first prospective study to investigate whether very early intervention in unborn children with congenital lower urinary tract obstruction (cLUTO) can improve their chances of survival and subsequent kidney function. The researchers aim to fundamentally improve the prognosis for this serious disease and ideally spare affected children from dialysis.</description>
                    <link>https://medicalxpress.com/news/2026-03-early-intervention-severe-fetal-megacystis.html</link>
                    <category></category>
                    <pubDate>Fri, 13 Mar 2026 16:00:03 EDT</pubDate>
                    <guid isPermaLink="false">news692627950</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/early-intervention-in.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Scan that makes prostate cancer cells glow could cut need for biopsies</title>
                    <description>An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings from the PRIMARY2 trial have been presented at the European Association of Urology Congress in London (EAU26).</description>
                    <link>https://medicalxpress.com/news/2026-03-scan-prostate-cancer-cells-biopsies.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Mar 2026 20:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news692523293</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/scan-that-makes-prosta-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Automated screening and education increase urinary incontinence diagnoses</title>
                    <description>Implementing an automated urinary incontinence screening and education program in primary care practices significantly increased awareness and treatment referrals in women with the condition, according to a recent study published in JAMA Internal Medicine.</description>
                    <link>https://medicalxpress.com/news/2026-03-automated-screening-urinary-incontinence.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Mar 2026 17:20:03 EDT</pubDate>
                    <guid isPermaLink="false">news692371982</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2021/treatment.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Study identifies gene linked to chemotherapy resistance in prostate cancer</title>
                    <description>A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings provide important new insights into why patients with metastatic disease often stop responding to a key class of life-prolonging chemotherapy drugs after initially benefiting. Given that taxanes remain the only chemotherapy agents with demonstrated survival benefit in advanced prostate cancer, understanding how and why resistance develops is an urgent need for patients.</description>
                    <link>https://medicalxpress.com/news/2026-03-gene-linked-chemotherapy-resistance-prostate.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Mar 2026 16:20:02 EDT</pubDate>
                    <guid isPermaLink="false">news692371600</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/study-identifies-gene.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Blood test predicts which bladder cancer patients may safely skip surgery</title>
                    <description>Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.</description>
                    <link>https://medicalxpress.com/news/2026-02-blood-bladder-cancer-patients-safely.html</link>
                    <category></category>
                    <pubDate>Fri, 27 Feb 2026 21:50:01 EST</pubDate>
                    <guid isPermaLink="false">news691419062</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/blood-test-predicts-wh.jpg" width="90" height="90" />
                                    </item>
                    </channel>
</rss>
